Toutes les actualités

Womed reduces the risks of female infertility

Information mise à jour le 17/10/18

Montpellier-based startup Womed won grand prize in the i-Lab 2018 competition for its highly innovative medical device: a polymer film that repairs the uterine wall and helps fight against certain types of female infertility

Womed réduit les risques d’infertilité féminine
The Montpellier startup Womed recently completed development of a highly innovative medical device that uses a polymer film as a mechanical barrier to eliminate adhesions that may occur on the uterine wall after surgery. 

To perform a curettage after a miscarriage or to remove a fibroma, the gynacologist scrapes the uterine wall, which can cause lesions that can stick together," explains Gonzague Issenmann, co-founder and CEO of Womed. “Poor healing of the uterus, which is the cause of miscarriage in one out of every five cases, is also the leading mechanical cause of infertility in women,” he adds.

The film placed by the surgeon right after the intervention keeps the walls separated during the first days of healing. It is biocompatible and biodegradable, transforming progressively into a gel that is evacuated naturally during the next cycle.

China, the second target market

The innovation was elaborated by Stéphanie Huberlandt, obstetrician gynecologist at the Nîmes CHU, and Xavier Garric, pharmacist, chemist, and professor at University of Montpellier. Both are co-founders of Womed. In June 2018, the startup won one of the grand prizes in the i-Lab 2018 competition, which recognizes the most remarkable projects.
Founded in 2018, Womed has four employees and is hosted by the University of Montpellier.

Montpellier Méditerranée Métropole is very involved in the health sector, and they want to follow young startups like ours. We are considering BIC hosting to join a dynamic and diverse entrepreneur network.”  

The company has plans to develop its activities internationally.

Every year, this innovation could concern five million medical interventions around the world,” adds Gonzague Issenmann.

He plans to release the device on the market within two years, starting in Europe.

China will be our second target market, where this type of infertility is common, notably because the abortion rate is particularly high,” concludes the CEO.

Il y a 0 commentaire sur cette page